Literature DB >> 28070871

Treating HIV Infection in the Central Nervous System.

A Calcagno1, G Di Perri2, S Bonora2.   

Abstract

Combination antiretroviral treatment is associated with clear benefits in HIV-positive subjects, and is also effective in the central nervous system (CNS), meaning HIV-associated dementia is now an uncommon event. Nevertheless, a significant number of patients show symptoms of neurocognitive impairment which may negatively affect their quality of life. Although several risk factors for HIV-associated neurocognitive disorders have been identified, there is no clear recommendation for their prevention and management. In this review, the penetration of drugs into the cerebrospinal fluid/CNS is discussed as well as the viral and clinical consequences associated with higher/lower compartmental exposure. We also review the potential interventions according to the currently identified underlying mechanisms, including persistent CNS immune activation, legacy effects, low-level viral replication and escape, co-morbidities, and antiretroviral-associated direct and indirect 'neurotoxicity'. Adjunctive therapies and interventions (including neuro-rehabilitation) are then briefly discussed. The treatment of HIV infection in the CNS is a complex area of therapeutics requiring multidisciplinary interventions and further study.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28070871     DOI: 10.1007/s40265-016-0678-9

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  105 in total

1.  Is there a role for maraviroc to treat HIV-associated central nervous system white matter disease?

Authors:  Colin Ball; Malur Sudhanva; Jozef Jarosz; Frank A Post; Elizabeth Hamlyn
Journal:  AIDS       Date:  2016-01       Impact factor: 4.177

2.  A pilot study of the effects of internet-based cognitive stimulation on neuropsychological function in HIV disease.

Authors:  James T Becker; Mary Amanda Dew; Howard J Aizenstein; Oscar L Lopez; Lisa Morrow; Judith Saxton; Lluís Tárraga
Journal:  Disabil Rehabil       Date:  2012-03-30       Impact factor: 3.033

3.  Cardiovascular risk factors associated with lower baseline cognitive performance in HIV-positive persons.

Authors:  E J Wright; B Grund; K Robertson; B J Brew; M Roediger; M P Bain; F Drummond; M J Vjecha; J Hoy; C Miller; A C Penalva de Oliveira; W Pumpradit; J C Shlay; W El-Sadr; R W Price
Journal:  Neurology       Date:  2010-08-11       Impact factor: 9.910

4.  Asymptomatic HIV-associated neurocognitive impairment increases risk for symptomatic decline.

Authors:  Igor Grant; Donald R Franklin; Reena Deutsch; Steven P Woods; Florin Vaida; Ronald J Ellis; Scott L Letendre; Thomas D Marcotte; J H Atkinson; Ann C Collier; Christina M Marra; David B Clifford; Benjamin B Gelman; Justin C McArthur; Susan Morgello; David M Simpson; John A McCutchan; Ian Abramson; Anthony Gamst; Christine Fennema-Notestine; Davey M Smith; Robert K Heaton
Journal:  Neurology       Date:  2014-05-09       Impact factor: 9.910

5.  Dendritic spine injury induced by the 8-hydroxy metabolite of efavirenz.

Authors:  Luis B Tovar-y-Romo; Namandjé N Bumpus; Daniel Pomerantz; Lindsay B Avery; Ned Sacktor; Justin C McArthur; Norman J Haughey
Journal:  J Pharmacol Exp Ther       Date:  2012-09-13       Impact factor: 4.030

6.  Neuropsychological Impairment in Acute HIV and the Effect of Immediate Antiretroviral Therapy.

Authors:  Idil Kore; Jintanat Ananworanich; Victor Valcour; James L K Fletcher; Thep Chalermchai; Robert Paul; Jesse Reynolds; Somporn Tipsuk; Sasiwimol Ubolyam; Somprartthana Rattanamanee; Linda Jagodzinski; Jerome Kim; Serena Spudich
Journal:  J Acquir Immune Defic Syndr       Date:  2015-12-01       Impact factor: 3.731

7.  Speed of processing training with middle-age and older adults with HIV: a pilot study.

Authors:  David E Vance; Pariya L Fazeli; Lesley A Ross; Virginia G Wadley; Karlene K Ball
Journal:  J Assoc Nurses AIDS Care       Date:  2012-05-11       Impact factor: 1.354

8.  Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study.

Authors:  Signe Westring Worm; Caroline Sabin; Rainer Weber; Peter Reiss; Wafaa El-Sadr; Francois Dabis; Stephane De Wit; Matthew Law; Antonella D'Arminio Monforte; Nina Friis-Møller; Ole Kirk; Eric Fontas; Ian Weller; Andrew Phillips; Jens Lundgren
Journal:  J Infect Dis       Date:  2010-02-01       Impact factor: 5.226

9.  Peripheral blood mononuclear cells HIV DNA levels impact intermittently on neurocognition.

Authors:  Lucette A Cysique; William J Hey-Cunningham; Nadene Dermody; Phillip Chan; Bruce J Brew; Kersten K Koelsch
Journal:  PLoS One       Date:  2015-04-08       Impact factor: 3.240

10.  Value of perfusion-weighted MR imaging in the assessment of early cerebral alterations in neurologically asymptomatic HIV-1-positive and HCV-positive patients.

Authors:  Joanna Bladowska; Brygida Knysz; Anna Zimny; Krzysztof Małyszczak; Anna Kołtowska; Paweł Szewczyk; Jacek Gąsiorowski; Michał Furdal; Marek J Sąsiadek
Journal:  PLoS One       Date:  2014-07-11       Impact factor: 3.240

View more
  4 in total

1.  Potent antiviral HIV-1 protease inhibitor combats highly drug resistant mutant PR20.

Authors:  Daniel W Kneller; Johnson Agniswamy; Arun K Ghosh; Irene T Weber
Journal:  Biochem Biophys Res Commun       Date:  2019-08-29       Impact factor: 3.575

Review 2.  Human microglial models to study HIV infection and neuropathogenesis: a literature overview and comparative analyses.

Authors:  Lot D de Witte; Monique Nijhuis; Stephanie B H Gumbs; Raphael Kübler; Lavina Gharu; Pauline J Schipper; Anne L Borst; Gijsje J L J Snijders; Paul R Ormel; Amber Berdenis van Berlekom; Annemarie M J Wensing
Journal:  J Neurovirol       Date:  2022-02-09       Impact factor: 3.739

3.  The Glucocorticoid Receptor Is a Critical Regulator of HIV Latency in Human Microglial Cells.

Authors:  David Alvarez-Carbonell; Fengchun Ye; Nirmala Ramanath; Curtis Dobrowolski; Jonathan Karn
Journal:  J Neuroimmune Pharmacol       Date:  2018-07-10       Impact factor: 4.147

Review 4.  DDRugging glioblastoma: understanding and targeting the DNA damage response to improve future therapies.

Authors:  Ola Rominiyi; Spencer J Collis
Journal:  Mol Oncol       Date:  2021-06-11       Impact factor: 6.603

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.